The strong beat and raised INGREZZA guidance signal accelerating commercial momentum across three products. Watch for the December 15 R&D Day for pipeline updates on osavampator (MDD) and direclidine (schizophrenia) Phase 3 readouts, which could drive further upside.
Drugs in focus
NBIX drug pipeline →direclidine
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 trials succeed, a potential FDA submission could occur in 2028, with approval possible in 2029 at the earliest, assuming topline data reads out in 2027 and a standard ~12-month review cycle.
- Next catalyst
- None dated
What to watchThe next hard catalyst is Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (timeline per Neurocrine's Q3 2026 earnings call on Nov 2, 2026). Positive data would validate direclidine as a potential competitor to the recently approved Cobenfy (KarXT) in the muscarinic agonist class; negative or mixed data would significantly hurt the stock given direclidine is one of Neurocrine's two late-stage pipeline assets.
Price Chart
Executive Summary
Neurocrine Biosciences reported Q3 2026 total revenue of $1.123B, up 41% YoY, with net product sales exceeding $1B for the first time. Non-GAAP EPS of $3.29 beat the $2.75 consensus, and revenue of $1.123B beat the $1.04B consensus. INGREZZA net sales guidance was raised to $2.9B-$2.925B from $2.825B-$2.875B.
Key Financial Metrics
Key Facts
- Total Q3 2026 revenue $1.123B, up 41% YoY from $795M
- Non-GAAP EPS $3.29 vs consensus $2.75 (beat by 19.6%)
- INGREZZA net sales $801M, up 17% YoY; guidance raised to $2.9B-$2.925B
- CRENESSITY net sales $211M, up 115% YoY
- VYKAT XR net sales $107M (first full quarter post-Soleno acquisition)
- GAAP net income $206.5M vs $209.5M YoY; Non-GAAP net income $347M vs $222M YoY
- Cash and marketable securities $790M at quarter end
Financial Impact
Revenue beat consensus by ~$83M (8%); EPS beat by $0.54 (19.6%); INGREZZA guidance raised by $75M at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| INGREZZA | $801.0M | +16.6% |
| CRENESSITY | $211.0M | +115.3% |
| VYKAT XR | $107.0M | Not reported |
Risk Factors
- Cash burn from R&D expansion and Soleno integration; cash dropped from $2.54B to $790M since year-end 2025
- GAAP net income flat YoY despite revenue growth, due to higher operating expenses and $52M unrealized loss on equity investments
- Dependence on INGREZZA for 71% of product sales; generic or competitive threats could erode the franchise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302926995 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 Viewing No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers